- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Bulletin from the 2025 Annual General Meeting of Spago Nanomedical AB | 139 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 14, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) - The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, May 14, 2025, at which the AGM... ► Artikel lesen | |
| SPAGO NANOMEDICAL Aktie jetzt für 0€ handeln | |||||
| 07.05. | Spago Nanomedical Interim Report January-March, 2025 | 194 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 7, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 338 (KSEK 350)The loss for the quarter amounted... ► Artikel lesen | |
| 15.04. | Spago Nanomedical Publishes The Annual Report for 2024 | 215 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)Spago Nanomedical's annual report for 2024 is from today available at the company's website, https://spagonanomedical.se/investor-relations/financial-reportsFor... ► Artikel lesen | |
| 09.04. | Notice To Annual General Meeting of Spago Nanomedical AB | 253 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 9, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)This English version of the notice to the Annual General Meeting is for convenience only. The Swedish version... ► Artikel lesen | |
| 04.04. | Spago on the increased dose in Tumorad-01 | 2 | Cision News | ||
| 20.03. | Nomination Committee's Proposal for a New Chairman and Composition of Spago Nanomedical's Board | 587 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 20, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the company's nomination committee proposes a changed board... ► Artikel lesen | |
| 06.03. | Spago takes Tumorad-01 study to the next level | 1 | Cision News | ||
| 04.03. | Spago Nanomedical Proceeds with Increased Dose in the Phase I/IIa study Tumorad-01 | 257 | ACCESS Newswire | LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose... ► Artikel lesen | |
| 06.02. | Spago Nanomedical year-end report January-December, 2024 | 239 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F)OCTOBER - DECEMBER IN BRIEFNet sales for the quarter amounted to KSEK 617 (KSEK 731)The loss for the quarter... ► Artikel lesen | |
| 15.01. | Spago Nanomedical Article on SPAGOPIX-01 Clinical Results Accepted for Publication in Investigative Radiology | 219 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / January 15, 2025 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that a manuscript on product candidate pegfosimer manganese has... ► Artikel lesen | |
| 19.12.24 | Spago's CEO: "We want to expand cancer treatment with effective radiopharmaceuticals" | 6 | Cision News | ||
| 18.12.24 | Second Patient Group Successfully Dosed in Spago Nanomedical's Phase I/IIa Study Tumorad-01 | 366 | ACCESS Newswire | LUND, SE / ACCESSWIRE / December 18, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that all patients in the second patient group have been dosed according... ► Artikel lesen | |
| 06.11.24 | Spago Nanomedical Interim Report January-September 2024 | 256 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / November 6, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Progress for the Tumorad programJULY - SEPTEMBER IN BRIEFNet sales for the quarter amounted to KSEK 485 (KSEK... ► Artikel lesen | |
| 21.10.24 | Nomination Committee Appointed for Spago Nanomedical's Annual General Meeting 2025 | 251 | ACCESS Newswire | LUND, SE / ACCESSWIRE / October 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) In accordance with the instructions to the nomination committee resolved by the Annual General Meeting ("AGM")... ► Artikel lesen | |
| 01.10.24 | Spago Nanomedical in New Phase with Full Focus on the Tumorad Program | 326 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / October 1, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Board of Directors of Spago Nanomedical AB (publ) has decided that the company's resources will be focused... ► Artikel lesen | |
| 27.08.24 | Spago Nanomedical's Phase I/IIa Study Tumorad-01 Continues Following Successful Treatment Completion of First Patient Group | 365 | ACCESS Newswire | LUND, SE / ACCESSWIRE / August 27, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) today announced that the independent Data Monitoring Committee (DMC) recommends to proceed... ► Artikel lesen | |
| 21.08.24 | Spago Nanomedical Interim Report January-June 2024 | 389 | ACCESS Newswire | LUND, SE / ACCESSWIRE / August 21, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Clinical and non-clinical progress in the Tumorad program APRIL - JUNE IN BRIEFNet sales for the quarter amounted... ► Artikel lesen | |
| 10.06.24 | Bulletin from the 2024 Annual General Meeting of Spago Nanomedical AB | 273 | ACCESS Newswire | LUND, SE / ACCESSWIRE / June 10, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) The Annual General Meeting (AGM) of Spago Nanomedical AB (publ) was held today, June 10, 2024, at which the AGM resolved... ► Artikel lesen | |
| 23.05.24 | Spago Nanomedical Receives Declarations of Intent from the Largest Owner, Board and Management Team Regarding the Exercise of TO12 | 311 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / May 23, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) ("Spago Nanomedical" or the "Company") has received declarations of intent from, among... ► Artikel lesen | |
| 20.05.24 | Spago Nanomedical Provides an Update on Tumorad-01 - Trial Proceeds as Planned | 610 | ACCESS Newswire | LUND, SWEDEN / ACCESSWIRE / May 20, 2024 / Spago Nanomedical (STO:SPAGO.ST)(FRA:7UX.F) Spago Nanomedical AB (publ) announced today that both of the clinical sites in the phase I/IIa study Tumorad-01... ► Artikel lesen |
Seite:
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TEMPUS AI | 62,60 | 0,00 % | Tempus AI: Starkes Wachstum - Verluste steigen jedoch weiter an | CHICAGO, Illinois (IT-Times) - Das Diagnose-Technologie-Unternehmen Tempus AI hat seine Ergebnisse für das erste Quartal 2025 bekannt gegeben und ein rasantes Wachstum vorgelegt. Tempus AI - Aktie:... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,075 | 0,00 % | Laufende Fusionskontrollverfahren: Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut, USA | Datum der Anmeldung:08.05.2025Aktenzeichen:B3-54/25Unternehmen:Merck KGaA, Darmstadt; Erwerb sämtlicher Anteile an und der alleinigen Kontrolle über SpringWorks Therapeutics, Inc., Stamford, Connecticut... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,250 | 0,00 % | Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock | ||
| SUMMIT THERAPEUTICS | 23,070 | 0,00 % | Summit Therapeutics Q1 2025 slides: Strong cash position supports advancing Ivonescimab pipeline | ||
| EVOTEC | 7,056 | +1,15 % | Evotec-Aktie mit leichten Kursgewinnen (7,086 €) | Im Plus liegt derzeit das Wertpapier von Evotec . Zuletzt zahlten Investoren für das Wertpapier 7,09 Euro. Am deutschen Aktienmarkt hat sich heute die Evotec-Aktie zwischenzeitlich um 2,99 Prozent verteuert.... ► Artikel lesen | |
| SEPTERNA | 10,100 | 0,00 % | Novo und Septerna kooperieren bei oralen Adipositas-Medikamenten | DJ Novo und Septerna kooperieren bei oralen Adipositas-Medikamenten
Von Dominic Chopping
DOW JONES--Das dänische Pharmaunternehmen Novo Nordisk hat eine Kooperationsvereinbarung mit dem US-Biotechunternehmen... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 13,640 | 0,00 % | Arcutis Biotherapeutics, Inc.: New Consensus Statements on Impact of Genital Psoriasis on Patients from Genital Psoriasis Wellness Consortium Published in Journal of the European Academy of Dermatology and Venereology Clinical Practice | ||
| ADMA BIOLOGICS | 19,200 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
| QIAGEN | 37,820 | +0,54 % | UBS stuft QIAGEN NV auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Qiagen auf "Neutral" mit einem Kursziel von 48 US-Dollar belassen. Den hohen Margen im Geschäft mit Laborverbrauchsmaterialien stehe sein fehlendes... ► Artikel lesen | |
| ARCELLX | 58,40 | 0,00 % | Arcellx GAAP EPS of -$1.13, revenue of $8.1M | ||
| AVIDITY BIOSCIENCES | 28,980 | +2,04 % | Avidity Biosciences stock price target cut to $68 by H.C. Wainwright | ||
| JANUX THERAPEUTICS | 23,290 | 0,00 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| BIONTECH | 83,30 | +0,97 % | Biotech Report: Evotec fest, Biontech leichter | (shareribs.com) Frankfurt / New York 09.05.2025 - Biotech-Aktien zeigten sich im deutschen Handel uneinheitlich. Evotec legten deutlich zu. Qiagen und Biontech gaben nach. Auch an der Wall Street verlor... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 2,560 | 0,00 % | Baird maintains Outperform on Taysha stock, reiterates $7 target | ||
| PHATHOM PHARMACEUTICALS | 3,480 | 0,00 % | Phathom Pharmaceuticals surges 50% following large insider purchase |
Das Unternehmen SPAGO NANOMEDICAL AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,85 % bei einem Aktienkurs von 0,016 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SPAGO NANOMEDICAL AB finden Sie auf Wallstreet Online.